Cargando…
Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein
Lipid nanoparticles (LNPs) are the most clinically advanced delivery system for RNA-based drugs but have predominantly been investigated for intravenous and intramuscular administration. Subcutaneous administration opens the possibility of patient self-administration and hence long-term chronic trea...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039535/ https://www.ncbi.nlm.nih.gov/pubmed/33868782 http://dx.doi.org/10.1016/j.omtn.2021.03.008 |
_version_ | 1783677612795625472 |
---|---|
author | Davies, Nigel Hovdal, Daniel Edmunds, Nicholas Nordberg, Peter Dahlén, Anders Dabkowska, Aleksandra Arteta, Marianna Yanez Radulescu, Aurel Kjellman, Tomas Höijer, Andreas Seeliger, Frank Holmedal, Elin Andihn, Elisabeth Bergenhem, Nils Sandinge, Ann-Sofie Johansson, Camilla Hultin, Leif Johansson, Marie Lindqvist, Johnny Björsson, Liselotte Jing, Yujia Bartesaghi, Stefano Lindfors, Lennart Andersson, Shalini |
author_facet | Davies, Nigel Hovdal, Daniel Edmunds, Nicholas Nordberg, Peter Dahlén, Anders Dabkowska, Aleksandra Arteta, Marianna Yanez Radulescu, Aurel Kjellman, Tomas Höijer, Andreas Seeliger, Frank Holmedal, Elin Andihn, Elisabeth Bergenhem, Nils Sandinge, Ann-Sofie Johansson, Camilla Hultin, Leif Johansson, Marie Lindqvist, Johnny Björsson, Liselotte Jing, Yujia Bartesaghi, Stefano Lindfors, Lennart Andersson, Shalini |
author_sort | Davies, Nigel |
collection | PubMed |
description | Lipid nanoparticles (LNPs) are the most clinically advanced delivery system for RNA-based drugs but have predominantly been investigated for intravenous and intramuscular administration. Subcutaneous administration opens the possibility of patient self-administration and hence long-term chronic treatment that could enable messenger RNA (mRNA) to be used as a novel modality for protein replacement or regenerative therapies. In this study, we show that subcutaneous administration of mRNA formulated within LNPs can result in measurable plasma exposure of a secreted protein. However, subcutaneous administration of mRNA formulated within LNPs was observed to be associated with dose-limiting inflammatory responses. To overcome this limitation, we investigated the concept of incorporating aliphatic ester prodrugs of anti-inflammatory steroids within LNPs, i.e., functionalized LNPs to suppress the inflammatory response. We show that the effectiveness of this approach depends on the alkyl chain length of the ester prodrug, which determines its retention at the site of administration. An unexpected additional benefit to this approach is the prolongation observed in the duration of protein expression. Our results demonstrate that subcutaneous administration of mRNA formulated in functionalized LNPs is a viable approach to achieving systemic levels of therapeutic proteins, which has the added benefits of being amenable to self-administration when chronic treatment is required. |
format | Online Article Text |
id | pubmed-8039535 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-80395352021-04-16 Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein Davies, Nigel Hovdal, Daniel Edmunds, Nicholas Nordberg, Peter Dahlén, Anders Dabkowska, Aleksandra Arteta, Marianna Yanez Radulescu, Aurel Kjellman, Tomas Höijer, Andreas Seeliger, Frank Holmedal, Elin Andihn, Elisabeth Bergenhem, Nils Sandinge, Ann-Sofie Johansson, Camilla Hultin, Leif Johansson, Marie Lindqvist, Johnny Björsson, Liselotte Jing, Yujia Bartesaghi, Stefano Lindfors, Lennart Andersson, Shalini Mol Ther Nucleic Acids Original Article Lipid nanoparticles (LNPs) are the most clinically advanced delivery system for RNA-based drugs but have predominantly been investigated for intravenous and intramuscular administration. Subcutaneous administration opens the possibility of patient self-administration and hence long-term chronic treatment that could enable messenger RNA (mRNA) to be used as a novel modality for protein replacement or regenerative therapies. In this study, we show that subcutaneous administration of mRNA formulated within LNPs can result in measurable plasma exposure of a secreted protein. However, subcutaneous administration of mRNA formulated within LNPs was observed to be associated with dose-limiting inflammatory responses. To overcome this limitation, we investigated the concept of incorporating aliphatic ester prodrugs of anti-inflammatory steroids within LNPs, i.e., functionalized LNPs to suppress the inflammatory response. We show that the effectiveness of this approach depends on the alkyl chain length of the ester prodrug, which determines its retention at the site of administration. An unexpected additional benefit to this approach is the prolongation observed in the duration of protein expression. Our results demonstrate that subcutaneous administration of mRNA formulated in functionalized LNPs is a viable approach to achieving systemic levels of therapeutic proteins, which has the added benefits of being amenable to self-administration when chronic treatment is required. American Society of Gene & Cell Therapy 2021-03-13 /pmc/articles/PMC8039535/ /pubmed/33868782 http://dx.doi.org/10.1016/j.omtn.2021.03.008 Text en © 2021 AstraZeneca AB https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Davies, Nigel Hovdal, Daniel Edmunds, Nicholas Nordberg, Peter Dahlén, Anders Dabkowska, Aleksandra Arteta, Marianna Yanez Radulescu, Aurel Kjellman, Tomas Höijer, Andreas Seeliger, Frank Holmedal, Elin Andihn, Elisabeth Bergenhem, Nils Sandinge, Ann-Sofie Johansson, Camilla Hultin, Leif Johansson, Marie Lindqvist, Johnny Björsson, Liselotte Jing, Yujia Bartesaghi, Stefano Lindfors, Lennart Andersson, Shalini Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein |
title | Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein |
title_full | Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein |
title_fullStr | Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein |
title_full_unstemmed | Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein |
title_short | Functionalized lipid nanoparticles for subcutaneous administration of mRNA to achieve systemic exposures of a therapeutic protein |
title_sort | functionalized lipid nanoparticles for subcutaneous administration of mrna to achieve systemic exposures of a therapeutic protein |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039535/ https://www.ncbi.nlm.nih.gov/pubmed/33868782 http://dx.doi.org/10.1016/j.omtn.2021.03.008 |
work_keys_str_mv | AT daviesnigel functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT hovdaldaniel functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT edmundsnicholas functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT nordbergpeter functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT dahlenanders functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT dabkowskaaleksandra functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT artetamariannayanez functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT radulescuaurel functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT kjellmantomas functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT hoijerandreas functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT seeligerfrank functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT holmedalelin functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT andihnelisabeth functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT bergenhemnils functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT sandingeannsofie functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT johanssoncamilla functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT hultinleif functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT johanssonmarie functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT lindqvistjohnny functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT bjorssonliselotte functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT jingyujia functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT bartesaghistefano functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT lindforslennart functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein AT anderssonshalini functionalizedlipidnanoparticlesforsubcutaneousadministrationofmrnatoachievesystemicexposuresofatherapeuticprotein |